Coldizin is scheduled for launch in the third quarter, in time for the ‘cough and cold season’, and Immulina is planned for launch in the fourth quarter. thin400 will be launched as soon as regulatory approval is granted, hopefully during the third quarter, said Scandinavian Clinical Nutrition (SCN).
Under the agreement, Vital Life will be responsible for product marketing and promotion, as well as local regulatory issues, supported by the expertise from SCN.
Danilo Copiz, vice president of sales at SCN, said: “I am pleased that we are taking the next step in our business relationship with Vital Life already. In March we agreed on exclusive rights for the cold product Coldizin, and now Vital Life takes the further step on committing to launch the diet product thin400 and the immune system product Immulina. I have high hopes in Vital Life and their integrated sales and marketing concept, and look forward to seeing the results of their work with our unique product portfolio.”